What is JRSIS HEALTH CARE CORP's earnings per share (EPS)?

JRSIS HEALTH CARE CORP (JRSS) reported diluted earnings per share of $0.00 for fiscal year 2023. This represents a 88.9% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

JRSIS HEALTH CARE CORP (JRSS) Financials

JRSS

FY2023 annual

Revenue $3.5M +159.2% YoY

Net Income -$81K +85.9% YoY

EPS (Diluted) $0.00 +88.9% YoY

Free Cash Flow $515K +128.5% YoY

Market Cap $1.3M as of Sep 22, 2026

Price / Sales 0.4x on $3.5M revenue, trailing 12 months to September 30, 2024

Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to September 30, 2024

Price / Book n/m negative shareholder equity, so no book multiple, Q3 FY2024

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 22, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2024, ended Sep 30, 2024 Reported Dec 20, 2024 Currency USD FYE December

Newest figures come from the 10-Q for Q3 FY2024, filed Dec 20, 2024. Each column of the statement tables below links to the filing it was taken from.

JRSIS HEALTH CARE CORP (JRSS) reported $3.5M in revenue for fiscal year 2023, up 159.2% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI JRSS FY2023 2026-08-30

A sharp revenue reset left a smaller business, where cash flow recovered ahead of profits while negative equity limits financial flexibility.

Cash generation reversed direction: operating cash flow moved from -$1.8M in FY2022 to $517K in FY2023, even though net income remained negative in both years. Because free cash flow nearly matched operating cash flow in FY2023, the improvement reflects cash-flow mechanics and limited reinvestment more than a self-sustaining earnings engine.

The FY2022 revenue reset left a much smaller operation: revenue recovered to $3.5M in FY2023 from $1.3M, but the business remains materially smaller than before the reset. Gross margin improved to 14.0% from 2.0%, yet that better unit economics has not translated into operating profitability.

Liabilities of $2.3M exceeded assets of $2.1M in FY2023, leaving little balance-sheet cushion. Current assets covered only 0.8x current liabilities, so short-term obligations still exceeded the resources classified as current.

Financial Health Signals

Financial health score not available

JRSIS HEALTH CARE CORP does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Altman Z-Score Distress

-0.84

JRSIS HEALTH CARE CORP scores -0.84, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($1.3M) relative to total liabilities ($2.3M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

6/8

JRSIS HEALTH CARE CORP passes 6 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 3 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Mixed

N/A

JRSIS HEALTH CARE CORP reported a net loss of $81K while generating $517K in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

JRSIS HEALTH CARE CORP reported an operating loss of $189K against $56K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$223K

YoY-55.2%

QoQ-62.7%

JRSIS HEALTH CARE CORP generated $223K in revenue in Q3 2024. This represents a decrease of 55.2% from the same quarter a year earlier. Against the prior quarter it is down 62.7%.

EBITDA

-$194K

YoY-465.9%

QoQ-81.7%

JRSIS HEALTH CARE CORP's EBITDA was -$194K in Q3 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 465.9% from the same quarter a year earlier. Against the prior quarter it is down 81.7%.

Net Income

-$188K

YoY-658.2%

QoQ-83.7%

JRSIS HEALTH CARE CORP reported -$188K in net income in Q3 2024. This represents a decrease of 658.2% from the same quarter a year earlier. Against the prior quarter it is down 83.7%.

EPS (Diluted)

$0.00

QoQ-120.0%

JRSIS HEALTH CARE CORP earned $0.00 per diluted share (EPS) in Q3 2024. Against the prior quarter it is down 120.0%.

Cash & Balance Sheet

Free Cash Flow

-$420K

YoY+6.4%

JRSIS HEALTH CARE CORP recorded an outflow of $420K in free cash flow in Q3 2024, representing a cash shortfall after capex. This represents an increase of 6.4% from the same quarter a year earlier.

Cash & Debt

$1K

YoY-95.9%

QoQ-99.7%

5Y CAGR-76.7%

10Y CAGR-48.8%

JRSIS HEALTH CARE CORP held $1K in cash against $6K in long-term debt as of Q3 2024, with $2.3M of liabilities due within a year.

Shares Outstanding

85M

QoQ0.0%

5Y CAGR+36.3%

JRSIS HEALTH CARE CORP had 85M shares outstanding in Q3 2024. It is unchanged from the prior quarter.

Dividends Per Share

Not reported for Q3 2024.

Margins & Returns

Gross Margin

12.1%

YoY-12.1pp

QoQ-19.1pp

JRSIS HEALTH CARE CORP's gross margin was 12.1% in Q3 2024, indicating the percentage of revenue retained after direct costs. This is down 12.1 percentage points from the same quarter a year earlier. Against the prior quarter it is down 19.1 percentage points.

Operating Margin

-92.5%

YoY-102.8pp

QoQ-72.6pp

JRSIS HEALTH CARE CORP's operating margin was -92.5% in Q3 2024, reflecting core business profitability. This is down 102.8 percentage points from the same quarter a year earlier. Against the prior quarter it is down 72.6 percentage points.

Net Margin

-84.4%

YoY-91.2pp

QoQ-67.3pp

JRSIS HEALTH CARE CORP's net profit margin was -84.4% in Q3 2024, showing the share of revenue converted to profit. This is down 91.2 percentage points from the same quarter a year earlier. Against the prior quarter it is down 67.3 percentage points.

Return on Equity

Not reported for Q3 2024.

Capital Allocation

R&D Spending

$29K

YoY-20.3%

QoQ+200.4%

JRSIS HEALTH CARE CORP invested $29K in research and development in Q3 2024. This represents a decrease of 20.3% from the same quarter a year earlier. Against the prior quarter it is up 200.4%.

Capital Expenditures

$68K

YoY-81.1%

JRSIS HEALTH CARE CORP invested $68K in capex in Q3 2024, funding long-term assets and infrastructure. This represents a decrease of 81.1% from the same quarter a year earlier.

Share Buybacks

Not reported for Q3 2024.

JRSS Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

JRSS quarterly income statement

Metric	TTM	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K
Revenue	$3.5M	$3.5M+159.2%	$1.3M-97.0%	$44.4M+24.3%	$35.7M+13.5%	$31.5M+10.8%	$28.4M+17.6%	$24.1M+33.3%	$18.1M+52.6%	$11.9M+98.5%	$6.0M+37.4%	$4.4M
Cost of Revenue	$3.0M	$3.0M+76.0%	$1.7M	N/A	N/A	N/A	N/A	$7.1M+44.5%	$4.9M+46.6%	$3.3M+92.0%	$1.7M+39.1%	$1.2M
Gross Profit	$442K	$483K+235.1%	-$358K	N/A	N/A	N/A	N/A	$17.1M+29.1%	$13.2M+55.0%	$8.5M+101.2%	$4.2M+36.8%	$3.1M
R&D Expenses	$133K	$189K-33.1%	$283K	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	$548K	$336K+18.6%	$283K	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Income	-$676K	-$189K+72.5%	-$685K-559.7%	-$104K-101.9%	$5.6M+19.8%	$4.7M-22.1%	$6.0M-10.0%	$6.7M+32.5%	$5.0M+91.0%	$2.6M+186.4%	$918K-30.3%	$1.3M
EBITDA	N/A	-$135K+80.1%	-$679K-119.6%	$3.5M-58.2%	$8.3M+20.5%	$6.9M-11.3%	$7.8M-2.1%	$7.9M+29.8%	$6.1M+74.3%	$3.5M+220.3%	$1.1M-23.8%	$1.4M
Interest Expense	$53K	$56K-12.8%	$65K-95.3%	$1.4M+21.5%	$1.1M+2.3%	$1.1M-1.9%	$1.1M-14.4%	$1.3M-4.3%	$1.4M+11.3%	$1.2M+23.0%	$1.0M+7823.8%	$13K
Income Tax	N/A	$9K	N/A	$1.2M-13.8%	$1.4M+108.2%	$658K-76.2%	$2.8M+109300.7%	$3K-37.7%	$4K+55.9%	$3K+20.7%	$2K+8.7%	$2K
Net Income	-$490K	-$81K+85.9%	-$576K-118.1%	$3.2M-16.7%	$3.8M+331.0%	$888K-55.4%	$2.0M-57.1%	$4.6M+33.8%	$3.5M+93.9%	$1.8M+192.8%	$611K+52.9%	$400K
EPS (Basic)	N/A	$0.00+88.9%	-$0.01-105.2%	$0.17+16.5%	$0.15+179.8%	$0.05-60.2%	$0.13	N/A	N/A	N/A	$0.05-84.4%	$0.29
EPS (Diluted)	$0.05	$0.00+88.9%	-$0.01	$0.17+16.6%	$0.15	$0.05-60.3%	$0.13	N/A	N/A	N/A	$0.05	$0.29
Diluted Shares (Avg)	N/A	77M+26.0%	61M	19M+2.1%	18M	17M+12.3%	15M	N/A	N/A	N/A	13M	1M

Metric	Q3'2410-Q	Q2'2410-Q	Q1'2410-Q	Q4'2310-Q	Q3'2310-Q	Q2'2310-Q	Q1'2310-Q	Q4'2210-K
Revenue	$223K-55.2%	$597K+77.1%	$500K+4.9%	$2.2M	$497K	$337K	$477K-96.9%	N/A
Cost of Revenue	$196K-48.0%	$411K+38.1%	$443K+36.1%	$2.0M	$377K	$298K	$326K	N/A
Gross Profit	$27K-77.6%	$186K+369.8%	$57K-62.2%	$172K	$120K	$40K	$151K	N/A
R&D Expenses	$29K-20.3%	$10K-75.0%	$10K-66.2%	$84K	$36K	$38K	$30K	N/A
SG&A Expenses	$97K+332.0%	$186K+57.0%	$101K+223.7%	$163K	$23K	$119K	$31K	N/A
Operating Income	-$206K-504.2%	-$119K+6.7%	-$161K-307.6%	-$190K	$51K+138.5%	-$127K0.0%	$78K+447.3%	N/A
EBITDA	-$194K-465.9%	-$107K+14.7%	-$149K-286.7%	-$142K	$53K+140.7%	-$125K+0.5%	$80K-90.7%	N/A
Interest Expense	$14K+18.6%	$16K+14.0%	$12K-39.7%	$11K	$12K	$14K	$20K-95.1%	N/A
Income Tax	$7+105.7%	$3K+2923.3%	N/A	$918	-$123	-$103	$8K-99.1%	N/A
Net Income	-$188K-658.2%	-$102K+3.4%	-$145K-419.8%	-$54K	$34K+125.4%	-$106K	$45K-98.3%	N/A
EPS (Basic)	$0.00-650.0%	$0.000.0%	$0.00-300.0%	$0.06-99.2%	$0.00+101.7%	$0.00+100.0%	$0.00-99.3%	$7.55+15991.0%
EPS (Diluted)	$0.00	$0.000.0%	$0.00	$0.06-99.2%	$0.00	$0.00+100.0%	$0.00	$7.55
Diluted Shares (Avg)	85M	85M+10.2%	84M	N/A	77M	77M+1649.6%	77M	N/A

JRSS Balance Sheet

JRSS quarterly balance sheet

Metric	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K
Total Assets	$2.1M+5.1%	$2.0M-97.3%	$75.7M+28.7%	$58.8M+13.9%	$51.6M-1.6%	$52.5M+7.8%	$48.7M+53.5%	$31.7M+14.3%	$27.7M+16.2%	$23.9M+28.9%	$18.5M
Current Assets	$1.8M+10.2%	$1.7M-88.0%	$13.9M+76.0%	$7.9M-17.2%	$9.5M-20.6%	$12.0M+16.8%	$10.3M+38.3%	$7.4M+76.3%	$4.2M+47.1%	$2.9M+126.0%	$1.3M
Cash & Equivalents	$118K+101.5%	$59K+96.4%	$30K-96.5%	$845K-57.1%	$2.0M+668.6%	$256K-71.0%	$884K-0.7%	$891K+152.9%	$352K-66.3%	$1.0M+65.8%	$631K
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$455K-19.0%	$562K-68.3%	$1.8M+21.5%	$1.5M+35.9%	$1.1M-7.8%	$1.2M+24.3%	$937K+16.9%	$801K+60.5%	$499K+176.3%	$181K+83.8%	$98K
Accounts Receivable	$715K+4.6%	$683K-90.9%	$7.5M+71.8%	$4.4M-4.2%	$4.6M-44.2%	$8.2M+44.6%	$5.7M+70.3%	$3.3M+66.0%	$2.0M+203.7%	$662K+143.8%	$271K
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$2.3M+9.3%	$2.1M-95.0%	$42.6M+42.1%	$30.0M+4.6%	$28.6M-5.9%	$30.4M+7.0%	$28.4M+42.1%	$20.0M-1.5%	$20.3M+7.7%	$18.9M+22.8%	$15.4M
Current Liabilities	$2.3M+8.2%	$2.1M-88.0%	$17.6M+49.7%	$11.8M+7.7%	$10.9M+52.2%	$7.2M+41.2%	$5.1M+57.9%	$3.2M+30.8%	$2.5M-17.3%	$3.0M+748.6%	$351K
Non-Current Liabilities	$25K+1016.3%	$2K-100.0%	$25.0M+37.3%	$18.2M+2.7%	$17.7M-23.8%	$23.3M-0.4%	$23.4M+39.1%	$16.8M-6.0%	$17.9M+12.3%	$15.9M+5.9%	$15.0M
Long-Term Debt	$25K	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$137K-135.1%	-$58K-100.2%	$33.1M+73.9%	$19.0M+28.5%	$14.8M+4.8%	$14.1M+9.6%	$12.9M+94.3%	$6.6M+79.9%	$3.7M+85.0%	$2.0M+320.8%	$474K
Retained Earnings	-$3.4M-2.4%	-$3.4M-79.1%	-$1.9M+54.3%	-$4.1M+39.5%	-$6.8M-152.6%	$12.9M+18.2%	$10.9M+74.1%	$6.3M+123.9%	$2.8M+177.0%	$1.0M+152.9%	$400K

Metric	Q3'2410-Q	Q2'2410-Q	Q1'2410-Q	Q4'2310-Q	Q3'2310-Q	Q2'2310-Q	Q1'2310-Q	Q4'2210-K
Total Assets	$2.1M+267.1%	$2.1M+219.6%	$2.1M+189.2%	$2.1M+5.1%	$565K-36.8%	$661K-35.5%	$729K-99.1%	$2.0M-97.3%
Current Assets	$1.8M+239.3%	$1.8M+195.9%	$1.8M+168.5%	$1.8M+10.2%	$527K-36.7%	$618K-35.3%	$676K-96.1%	$1.7M-88.0%
Cash & Equivalents	$1K-95.9%	$446K+1480.1%	$324K+1623.4%	$118K+101.5%	$33K+201.2%	$28K-25.1%	$19K-99.0%	$59K+96.4%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$362K	$398K	$446K	$455K-19.0%	N/A	N/A	N/A	$562K-68.3%
Accounts Receivable	$575K	$556K+3930.4%	$603K	$715K+4.6%	N/A	$14K	N/A	$683K-90.9%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$2.3M+2436.4%	$2.1M+2963.6%	$2.4M+6433.6%	$2.3M+9.3%	$91K+175.3%	$69K+89.8%	$37K-99.9%	$2.1M-95.0%
Current Liabilities	$2.3M+2429.5%	$2.1M+2946.0%	$2.4M+6383.8%	$2.3M+8.2%	$91K+230.5%	$69K+163.1%	$37K-99.8%	$2.1M-88.0%
Non-Current Liabilities	$6K	$12K	$18K	$25K+1016.3%	$0-100.0%	$0-100.0%	$0-100.0%	$2K-100.0%
Long-Term Debt	$6K	$12K	$18K	$25K	N/A	N/A	N/A	N/A
Total Equity	-$198K-141.7%	-$7K-101.3%	-$260K-137.6%	-$137K-135.1%	$474K-45.0%	$592K-40.2%	$692K-98.1%	-$58K-100.2%
Retained Earnings	-$3.9M+83.9%	-$3.7M+84.6%	-$3.6M+84.9%	-$3.4M-2.4%	-$24.0M-1.6%	-$23.9M-1.7%	-$23.8M-78986.8%	-$3.4M-79.1%

Not reported in any period shown, so not listed: Goodwill.

JRSS Cash Flow Statement

JRSS quarterly cash flow statement

Metric	TTM	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K
Operating Cash Flow	-$730K	$517K+129.3%	-$1.8M-121.4%	$8.2M-22.6%	$10.6M-10.2%	$11.8M+28.8%	$9.2M+10.3%	$8.3M+67.2%	$5.0M+97.0%	$2.5M+23.2%	$2.1M+106.8%	$993K
Depreciation & Amortization	N/A	$54K+828.5%	$6K-99.8%	$3.6M+32.5%	$2.7M+21.9%	$2.2M+25.3%	$1.8M+39.1%	$1.3M+17.3%	$1.1M+24.0%	$872K+397.4%	$175K+50.6%	$116K
Stock-Based Compensation	N/A	N/A	$245K	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Capital Expenditures	N/A	$1K-96.7%	$45K-98.1%	$2.3M-72.1%	$8.3M+75.5%	$4.7M+43.8%	$3.3M+26.5%	$2.6M-25.5%	$3.5M-32.6%	$5.2M+43.4%	$3.6M+412.2%	$702K
Free Cash Flow	N/A	$515K+128.5%	-$1.8M-130.5%	$5.9M+150.0%	$2.4M-66.8%	$7.1M+20.5%	$5.9M+3.0%	$5.7M+280.4%	$1.5M+157.6%	-$2.6M-70.4%	-$1.5M-627.6%	$292K
Investing Cash Flow	N/A	$19K+100.7%	-$2.8M+48.6%	-$5.5M+33.5%	-$8.3M-108.7%	-$4.0M+33.6%	-$6.0M+55.7%	-$13.5M-272.9%	-$3.6M	N/A	N/A	N/A
Financing Cash Flow	$728K	-$568K-130.6%	$1.9M+166.4%	-$2.8M+18.4%	-$3.4M+43.9%	-$6.1M-55.7%	-$3.9M-175.9%	$5.2M+765.9%	-$776K	N/A	N/A	N/A

Metric	Q3'2410-Q	Q2'2410-Q	Q1'2410-Q	Q4'2310-Q	Q3'2310-Q	Q2'2310-Q	Q1'2310-Q	Q4'2210-K
Operating Cash Flow	-$352K-291.3%	-$269K-151.0%	-$205K-1141.5%	$96K+102.0%	-$90K-175.1%	$528K+133.3%	-$17K-100.4%	-$4.8M-657.5%
Depreciation & Amortization	$12K+502.5%	$12K+470.9%	$12K+470.5%	$13K	$2K-6.9%	$2K+38.6%	$2K-99.8%	N/A
Stock-Based Compensation	N/A	N/A	N/A	N/A	N/A	N/A	$82K	N/A
Capital Expenditures	$68K-81.1%	N/A	N/A	$1K-28.3%	-$359K+19290.8%	N/A	N/A	-$2K-99.7%
Free Cash Flow	-$420K+6.4%	N/A	N/A	$95K+102.0%	-$449K-1197.2%	N/A	N/A	-$4.8M-2075.1%
Investing Cash Flow	-$22	N/A	N/A	$19K+1010.5%	N/A	N/A	N/A	$2K-99.8%
Financing Cash Flow	-$96K+72.6%	$403K+583.6%	$413K+388.6%	$8K-99.7%	-$350K	-$83K-164.4%	-$143K+83.5%	$2.6M+268.8%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

JRSS Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

JRSS quarterly financial ratios

Metric	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K
Gross Margin	14.0%+40.7pp	-26.8%	N/A	N/A	N/A	N/A	70.8%-2.3pp	73.0%+1.1pp	71.9%+1.0pp	71.0%-0.3pp	71.3%
Operating Margin	-5.5%+45.8pp	-51.3%-51.1pp	-0.2%-15.9pp	15.7%+0.8pp	14.8%-6.3pp	21.1%-6.5pp	27.6%-0.2pp	27.7%+5.6pp	22.1%+6.8pp	15.3%-14.9pp	30.3%
Net Margin	-2.3%+40.8pp	-43.1%-50.3pp	7.2%-3.5pp	10.7%+7.9pp	2.8%-4.2pp	7.0%-12.2pp	19.2%+0.1pp	19.2%+4.1pp	15.1%+4.8pp	10.2%+1.0pp	9.2%
Return on Equity	N/A	N/A	9.6%-10.5pp	20.1%+14.1pp	6.0%-8.1pp	14.1%-21.9pp	36.0%-16.3pp	52.3%+3.8pp	48.6%+17.9pp	30.7%-53.7pp	84.4%
Return on Assets	-3.8%+24.4pp	-28.2%-32.4pp	4.2%-2.3pp	6.5%+4.8pp	1.7%-2.1pp	3.8%-5.8pp	9.6%-1.4pp	10.9%+4.5pp	6.5%+3.9pp	2.6%+0.4pp	2.2%
Current Ratio	0.800.0x	0.790.0x	0.79+0.1x	0.67-0.2x	0.87-0.8x	1.67-0.3x	2.02-0.3x	2.31+0.6x	1.71+0.7x	0.96-2.6x	3.61
Debt-to-Equity	N/A	N/A	1.29-0.3x	1.57-0.4x	1.93-0.2x	2.15-0.1x	2.21-0.8x	3.02-2.5x	5.51-4.0x	9.47-23.0x	32.45
Asset Turnover	1.61+1.0x	0.65+0.1x	0.590.0x	0.610.0x	0.61+0.1x	0.540.0x	0.50-0.1x	0.57+0.1x	0.43+0.2x	0.250.0x	0.23
FCF Margin	14.9%	-135.5%	13.4%+6.7pp	6.6%-16.0pp	22.7%+1.8pp	20.8%-2.9pp	23.8%+15.5pp	8.3%+30.4pp	-22.1%+3.7pp	-25.7%-32.4pp	6.7%

Metric	Q3'2410-Q	Q2'2410-Q	Q1'2410-Q	Q4'2310-Q	Q3'2310-Q	Q2'2310-Q	Q1'2310-Q	Q4'2210-K
Gross Margin	12.1%-12.1pp	31.1%+19.4pp	11.4%-20.3pp	8.0%	24.1%	11.7%	31.7%	N/A
Operating Margin	-92.5%-102.8pp	-19.9%+17.9pp	-32.1%-48.4pp	-8.8%	10.3%	-37.7%	16.3%+16.4pp	N/A
Net Margin	-84.4%-91.2pp	-17.2%+14.3pp	-29.0%-38.6pp	-2.5%	6.8%	-31.4%	9.5%-7.4pp	N/A
Return on Equity	N/A	N/A	N/A	N/A	7.1%+22.5pp	-17.9%	6.6%-0.8pp	N/A
Return on Assets	-9.1%-15.1pp	-4.9%+11.2pp	-6.9%-13.1pp	-2.5%	6.0%+20.8pp	-16.0%	6.2%+3.0pp	N/A
Current Ratio	0.78-5.0x	0.86-8.0x	0.76-17.5x	0.800.0x	5.79-24.4x	8.90-27.3x	18.30+17.4x	0.790.0x
Debt-to-Equity	N/A	N/A	N/A	N/A	0.19+0.2x	0.12+0.1x	0.05-1.2x	N/A
Asset Turnover	0.11-0.8x	0.28-0.2x	0.24-0.4x	1.00	0.88	0.51	0.65+0.5x	N/A
FCF Margin	-188.4%	N/A	N/A	4.4%	-90.2%	N/A	N/A	N/A

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: FCF Margin.

Note: Shareholder equity is negative (-$137K), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.80), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
JRSIS HEALTH CARE CORP JRSS	FY2023	$3.5M	-$81K	-2.3%	$1.3M	—
SHOREPOWER TECHNOLOGIES SPEV	FY2025	$204K	-$337K	N/A	$7.8M	—
GHST WORLD INC GHST	FY2025	N/A	N/A	N/A	$4.7M	—

Where JRSIS HEALTH CARE CORP Ranks

Frequently Asked Questions

What is JRSIS HEALTH CARE CORP's annual revenue?

JRSIS HEALTH CARE CORP (JRSS) reported $3.5M in total revenue for fiscal year 2023. This represents a 159.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is JRSIS HEALTH CARE CORP's revenue growing?

JRSIS HEALTH CARE CORP (JRSS) revenue grew by 159.2% year-over-year, from $1.3M to $3.5M in fiscal year 2023.

Is JRSIS HEALTH CARE CORP profitable?

No, JRSIS HEALTH CARE CORP (JRSS) reported a net income of -$81K in fiscal year 2023, with a net profit margin of -2.3%.

What is JRSIS HEALTH CARE CORP's EBITDA?

JRSIS HEALTH CARE CORP (JRSS) had EBITDA of -$135K in fiscal year 2023, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does JRSIS HEALTH CARE CORP have?

As of fiscal year 2023, JRSIS HEALTH CARE CORP (JRSS) had $118K in cash and equivalents against $25K in long-term debt.

What is JRSIS HEALTH CARE CORP's gross margin?

JRSIS HEALTH CARE CORP (JRSS) had a gross margin of 14.0% in fiscal year 2023, indicating the percentage of revenue retained after direct costs of goods sold.

What is JRSIS HEALTH CARE CORP's operating margin?

JRSIS HEALTH CARE CORP (JRSS) had an operating margin of -5.5% in fiscal year 2023, reflecting the profitability of core business operations before interest and taxes.

What is JRSIS HEALTH CARE CORP's net profit margin?

JRSIS HEALTH CARE CORP (JRSS) had a net profit margin of -2.3% in fiscal year 2023, representing the share of revenue converted into profit after all expenses.

What is JRSIS HEALTH CARE CORP's free cash flow?

JRSIS HEALTH CARE CORP (JRSS) generated $515K in free cash flow during fiscal year 2023. This represents a 128.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is JRSIS HEALTH CARE CORP's operating cash flow?

JRSIS HEALTH CARE CORP (JRSS) generated $517K in operating cash flow during fiscal year 2023, representing cash generated from core business activities.

What are JRSIS HEALTH CARE CORP's total assets?

JRSIS HEALTH CARE CORP (JRSS) had $2.1M in total assets as of fiscal year 2023, including both current and long-term assets.

What are JRSIS HEALTH CARE CORP's capital expenditures?

JRSIS HEALTH CARE CORP (JRSS) invested $1K in capital expenditures during fiscal year 2023, funding long-term assets and infrastructure.

How much does JRSIS HEALTH CARE CORP spend on research and development?

JRSIS HEALTH CARE CORP (JRSS) invested $189K in research and development during fiscal year 2023.

How many shares does JRSIS HEALTH CARE CORP have outstanding?

JRSIS HEALTH CARE CORP (JRSS) had 85M shares outstanding as of fiscal year 2023.

What is JRSIS HEALTH CARE CORP's current ratio?

JRSIS HEALTH CARE CORP (JRSS) had a current ratio of 0.80 as of fiscal year 2023, which is below 1.0, which may suggest potential liquidity concerns.

What is JRSIS HEALTH CARE CORP's return on assets (ROA)?

JRSIS HEALTH CARE CORP (JRSS) had a return on assets of -3.8% for fiscal year 2023, measuring how efficiently the company uses its assets to generate profit.

What is JRSIS HEALTH CARE CORP's P/E ratio?

JRSIS HEALTH CARE CORP (JRSS) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to September 30, 2024). The market capitalization is $1.3M as of Sep 22, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is JRSIS HEALTH CARE CORP's price-to-sales ratio?

JRSIS HEALTH CARE CORP (JRSS) trades at 0.4x sales, its market capitalization divided by revenue of $3.5M revenue, trailing 12 months to September 30, 2024. The market capitalization is $1.3M as of Sep 22, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Why is JRSIS HEALTH CARE CORP's debt-to-equity ratio negative or not reported?

JRSIS HEALTH CARE CORP (JRSS) has negative shareholder equity of -$137K as of fiscal year 2023, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is JRSIS HEALTH CARE CORP's Altman Z-Score?

JRSIS HEALTH CARE CORP (JRSS) has an Altman Z-Score of -0.84, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is JRSIS HEALTH CARE CORP's Piotroski F-Score?

JRSIS HEALTH CARE CORP (JRSS) has a Piotroski F-Score of 6 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are JRSIS HEALTH CARE CORP's earnings high quality?

JRSIS HEALTH CARE CORP (JRSS) reported a net loss of $81K while generating $517K in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can JRSIS HEALTH CARE CORP cover its interest payments?

JRSIS HEALTH CARE CORP (JRSS) reported an operating loss of $189K against $56K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.